<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570995</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00068607</org_study_id>
    <nct_id>NCT04570995</nct_id>
  </id_info>
  <brief_title>Effect of Fish Oil on Athlete's Executive Function</brief_title>
  <official_title>Effect of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) on Brain Executive Function in Student Athletes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine the impact of long chain omega-3 PUFA (Polyunsaturated&#xD;
      fatty acids) supplementation on executive function in collegiate athletes in a randomized,&#xD;
      double-blind, placebo-controlled trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to determine the effect of daily oral intake of a fish&#xD;
      oil capsule enriched in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on brain&#xD;
      EF (Executive Function) and blood-based biomarkers among male collegiate baseball student&#xD;
      athletes over the course of an academic school year&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor unable to send smaller necessary capsules&#xD;
  </why_stopped>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind, placebo-controlled, two-arm intervention study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The capsules are of nearly identical color rendering them indistinguishable in appearance</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Barkley Deficits in Executive Functioning Scale (BDEFS)</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>Evaluate dimensions of adult executive functioning in daily life - self administered - Items are answered on a 4-point scale ranging from &quot;1= Never or rarely&quot; to &quot; 4 = Very often&quot;; Î±'s range from 0.91 to 0.96. Higher scores are interpreted as indicating greater deficits in EF - The Barkley Deficits in Executive Functioning Scale is an 89 item self-report measure of executive functioning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroop Test</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>Subjects will be asked to read words of colors, state the colors of various letters to test processing speed, and state the color of the font of a word when the actual word describes a conflicting color to test response inhibition (executive functioning).&#xD;
Three scores, as well as an interference score, are generated using the number of items completed on each page, with higher scores reflecting better performance and less interference on reading ability. T-Scores of 40 or less are considered &quot;low.&quot; Word, color, and color-word T-Scores above 40 or are considered &quot;normal&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroop Test</measure>
    <time_frame>Baseline, Day 1</time_frame>
    <description>Subjects will be asked to read words of colors, state the colors of various letters to test processing speed, and state the color of the font of a word when the actual word describes a conflicting color to test response inhibition (executive functioning).&#xD;
Three scores, as well as an interference score, are generated using the number of items completed on each page, with higher scores reflecting better performance and less interference on reading ability. T-Scores of 40 or less are considered &quot;low.&quot; Word, color, and color-word T-Scores above 40 or are considered &quot;normal&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trail Making Test</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>Visual attention, task switching - self administered - The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.&#xD;
The test results are reported as the time that took to complete. Longer times denotes worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trail Making Test</measure>
    <time_frame>Baseline, Day 1</time_frame>
    <description>Visual attention, task switching - self administered - The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.&#xD;
The test results are reported as the time that took to complete. Longer times denotes worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stop-Signal Test</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>Response inhibition - self administered - stop signal task is a test of inhibition of prepotent responses. It requires the participant to respond as quickly as possible to a predetermined stimulus, the go trial, but to abort any response when a subsequently presented stop signal is displayed.&#xD;
Speed and accuracy on the go trials are measured. The stop signal reaction time is calculated and reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stop-Signal Test</measure>
    <time_frame>Baseline, Day 1</time_frame>
    <description>Response inhibition - self administered - stop signal task is a test of inhibition of prepotent responses. It requires the participant to respond as quickly as possible to a predetermined stimulus, the go trial, but to abort any response when a subsequently presented stop signal is displayed.&#xD;
Speed and accuracy on the go trials are measured. The stop signal reaction time is calculated and reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Digit Span</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>Working memory - self administered -Digit Span measures verbal short-term memory, defined as the system that allows for temporary storage of information, and is crucial in everyday tasks such as remembering a telephone number or understanding long sentences - The average digit span for normal adults without error is seven plus or minus two. The Digit Span test is a measure of verbal short-term/working memory. Scores range from 0 to 28, with higher scores indicating better verbal short-term/working memory.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Digit Span</measure>
    <time_frame>Baseline, Day 1</time_frame>
    <description>Working memory - self administered -Digit Span measures verbal short-term memory, defined as the system that allows for temporary storage of information, and is crucial in everyday tasks such as remembering a telephone number or understanding long sentences - The average digit span for normal adults without error is seven plus or minus two. The Digit Span test is a measure of verbal short-term/working memory. Scores range from 0 to 28, with higher scores indicating better verbal short-term/working memory.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wisconsin Card Sort Test</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>Will be administered to assess preservation and abstract thinking. The The task measures how well people can adapt to the changing rules, and their cognitive flexibility.&#xD;
The number of perseverative errors in Wisconsin Card Sorting Task is the most robust variable of the task to assess cognitive flexibility. Higher scores show an impairment of cognitive flexibility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wisconsin Card Sort Test</measure>
    <time_frame>Baseline, Day 1</time_frame>
    <description>Will be administered to assess preservation and abstract thinking. The The task measures how well people can adapt to the changing rules, and their cognitive flexibility.&#xD;
The number of perseverative errors in Wisconsin Card Sorting Task is the most robust variable of the task to assess cognitive flexibility. Higher scores show an impairment of cognitive flexibility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating levels of fatty acids - EPA (eicosapentaenoic acid) in plasma</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>centrifuged to isolate plasma for EPA fatty acid analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating levels of fatty acids - EPA on red blood cells</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>centrifuged to isolate red blood cells for EPA fatty acid analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating levels of fatty acids - DHA (docosahexaenoic acid) on Red blood cells</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>centrifuged to isolate red blood cells for DHA fatty acid analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating levels of fatty acids - DHA in plasma</measure>
    <time_frame>visit #2 (~6-8 weeks after baseline)</time_frame>
    <description>centrifuged to isolate plasma for DHA fatty acid analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Capsule consumption compliance</measure>
    <time_frame>Visits 2 (Week~6-8 weeks after baseline ) and visit 5 (up to 9 months)</time_frame>
    <description>Percentage capsules taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumferences</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression, Anxiety and Stress Scale (DASS)</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
    <description>Designed to measure the negative emotional states of depression, anxiety and stress - It consists of three 14-item subscales with each item scored on a 4-point Likert scale, ranging from 0 (did not apply to me at all) to 3 (applied to me very much, or most of the time). Total scores are calculated by summing the items on each subscale, giving a score range of 0-42 on each subscale. Scores above 20, 14 and 25 on the depression, anxiety and stress subscales respectively are indicative of severe levels. Higher scores denotes worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and/or injury biomarkers (e.g., isoprostanes)</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
    <description>quantify plasma levels of inflammatory biomarker assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of inflammatory and/or injury biomarkers (creatinine kinase)</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of inflammatory and/or injury biomarkers (ROS) (Reactive oxygen species)</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
    <description>quantify plasma levels of inflammatory biomarker assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Inflammatory and/or injury biomarkers (IGF) (Insulin-like growth factor 1)</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
    <description>quantify plasma levels of inflammatory biomarker assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of inflammatory and/or injury biomarkers (TNF) (Tumor necrosis factor)</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
    <description>quantify plasma levels of inflammatory biomarker assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of inflammatory and/or injury biomarkers (CRP) (C-reactive protein)</measure>
    <time_frame>Visits 1 to 5, from baseline up to 9 months</time_frame>
    <description>quantify plasma levels of inflammatory biomarker assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of inflammatory biomarkers (IL-6, IL-8, IL-10) (Interleukin)</measure>
    <time_frame>Post study - 9 months</time_frame>
    <description>quantify plasma levels of inflammatory biomarker assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep patterns</measure>
    <time_frame>4 Visits during 9 months (approximately 6-8 week intervals)</time_frame>
    <description>Time spent in each sleep stage: Light, REM, Slow Wave (Deep), and Awake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reaction time assessment</measure>
    <time_frame>weekly intervals for 9 months of study</time_frame>
    <description>Baseball performance, assessed by reaction time assessment using the DynaVision system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>From baseline up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>From baseline up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>From baseline up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barkley Deficits in Executive Functioning Scale (BDEFS)</measure>
    <time_frame>From Visit 3 (week ~12-16 weeks after baseline) to visit 5 (up to 9 months)</time_frame>
    <description>Evaluate dimensions of adult executive functioning in daily life - self administered - Items are answered on a 4-point scale ranging from &quot;1= Never or rarely&quot; to &quot; 4 = Very often&quot;; Î±'s range from 0.91 to 0.96. Higher scores are interpreted as indicating greater deficits in EF - The Barkley Deficits in Executive Functioning Scale is an 89 item self-report measure of executive functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop Test</measure>
    <time_frame>From Visit 3 (week ~12-16 weeks after baseline) to visit 5 (up to 9 months)</time_frame>
    <description>Subjects will be asked to read words of colors, state the colors of various letters to test processing speed, and state the color of the font of a word when the actual word describes a conflicting color to test response inhibition (executive functioning).&#xD;
Three scores, as well as an interference score, are generated using the number of items completed on each page, with higher scores reflecting better performance and less interference on reading ability. T-Scores of 40 or less are considered &quot;low.&quot; Word, color, and color-word T-Scores above 40 or are considered &quot;normal&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test</measure>
    <time_frame>From Visit 3 (week ~12-16 weeks after baseline) to visit 5 (up to 9 months)</time_frame>
    <description>Visual attention, task switching - self administered - The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.&#xD;
The test results are reported as the time that took to complete. Longer times denotes worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stop-Signal Test</measure>
    <time_frame>From Visit 3 (week ~12-16 weeks after baseline) to visit 5 (up to 9 months)</time_frame>
    <description>Response inhibition - self administered - stop signal task is a test of inhibition of prepotent responses. It requires the participant to respond as quickly as possible to a predetermined stimulus, the go trial, but to abort any response when a subsequently presented stop signal is displayed.&#xD;
Speed and accuracy on the go trials are measured. The stop signal reaction time is calculated and reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Span</measure>
    <time_frame>From Visit 3 (week ~12-16 weeks after baseline) to visit 5 (up to 9 months)</time_frame>
    <description>Working memory - self administered -Digit Span measures verbal short-term memory, defined as the system that allows for temporary storage of information, and is crucial in everyday tasks such as remembering a telephone number or understanding long sentences - The average digit span for normal adults without error is seven plus or minus two. The Digit Span test is a measure of verbal short-term/working memory. Scores range from 0 to 28, with higher scores indicating better verbal short-term/working memory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wisconsin Card Sort Test</measure>
    <time_frame>From Visit 3 (week ~12-16 weeks after baseline) to visit 5 (up to 9 months)</time_frame>
    <description>Will be administered to assess preservation and abstract thinking. The The task measures how well people can adapt to the changing rules, and their cognitive flexibility.&#xD;
The number of perseverative errors in Wisconsin Card Sorting Task is the most robust variable of the task to assess cognitive flexibility. Higher scores show an impairment of cognitive flexibility.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Brain Health</condition>
  <condition>Brain Function</condition>
  <condition>Brain Development</condition>
  <arm_group>
    <arm_group_label>fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants will be asked to consume a daily (5 days per week) dietary supplement containing fish oil encapsulated in soft gel capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>safflower oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants will be asked to consume a daily (5 days per week) dietary supplement containing a placebo oil product (safflower oil) encapsulated in soft gel capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week</description>
    <arm_group_label>fish oil</arm_group_label>
    <other_name>eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Safflower Oil</intervention_name>
    <description>Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week</description>
    <arm_group_label>safflower oil</arm_group_label>
    <other_name>high oleic acid (18:1, monounsaturated fatty acid)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Wake Forest University National Collegiate Athletic Association (NCAA) Division I&#xD;
             baseball male student athletes cleared to participate in university athletics as&#xD;
             determined by the team physician&#xD;
&#xD;
          -  Age &gt;/=18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness to consume a daily dietary supplement over the course of the study&#xD;
&#xD;
          -  Allergy to dietary supplement components&#xD;
&#xD;
          -  Lipid-lowering medication use&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaheh Rahbar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Innis SM. Dietary omega 3 fatty acids and the developing brain. Brain Res. 2008 Oct 27;1237:35-43. doi: 10.1016/j.brainres.2008.08.078. Epub 2008 Sep 9. Review.</citation>
    <PMID>18789910</PMID>
  </reference>
  <reference>
    <citation>McNamara RK, Able J, Jandacek R, Rider T, Tso P, Eliassen JC, Alfieri D, Weber W, Jarvis K, DelBello MP, Strakowski SM, Adler CM. Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study. Am J Clin Nutr. 2010 Apr;91(4):1060-7. doi: 10.3945/ajcn.2009.28549. Epub 2010 Feb 3.</citation>
    <PMID>20130094</PMID>
  </reference>
  <reference>
    <citation>Vesco AT, Young AS, Arnold LE, Fristad MA. Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: secondary analyses of the omega 3 and therapy (OATS) trials. J Child Psychol Psychiatry. 2018 Jun;59(6):628-636. doi: 10.1111/jcpp.12830. Epub 2017 Oct 24.</citation>
    <PMID>29063592</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polyunsaturated fatty Acids</keyword>
  <keyword>Executive Function abilities</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

